Status:

RECRUITING

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

Lead Sponsor:

China Medical University Hospital

Conditions:

Schizophrenia

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents w...

Detailed Description

The current treatment for schizophrenia remains unsatisfactory; thus, development of new treatments is vital. Both sigma-1 receptor (S1R) dysfunction and NMDA receptor (NMDAR) hypofunction contribute ...

Eligibility Criteria

Inclusion

  • Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia
  • Are resistant to adequate treatments of at least two antipsychotics (excluding clozapine)
  • Remain symptomatic but without clinically significant fluctuation, while their antipsychotic doses are unchanged for at least 3 months and will be maintained during the period of the 8-week trial
  • PANSS total score \>70
  • Hamilton Depression Rating Scale-17 items (HAMD) \<7
  • Are physically healthy and laboratory assessments (including blood routine, biochemical tests) are clinically insignificant.
  • Have sufficient education to communicate effectively and are capable of completing the assessments of the study.
  • Agree to participate in the study and provide informed consent

Exclusion

  • DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder
  • History of epilepsy, head trauma, central nervous system diseases or mental disorders other than schizophrenia (including major depressive disorder, bipolar disorders, persistent depressive disorder, obsessive-compulsive disorder)
  • Pregnancy or lactation
  • Inability to follow protocol

Key Trial Info

Start Date :

September 23 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2029

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT06574360

Start Date

September 23 2024

End Date

March 1 2029

Last Update

October 8 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan